Gocovri Disease Interactions
There are 7 disease interactions with Gocovri (amantadine).
- Psychoses/depression
- Renal dysfunction
- Seizure disorders
- Hypotension
- Psychosis
- CHF/edema
- Hypotension
Amantadine (applies to Gocovri) psychoses/depression
Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, History - Psychiatric Disorder, Alcoholism, Drug Abuse/Dependence
Amantadine may precipitate or exacerbate psychotic symptoms. Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza. Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly. It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.
Amantadine (applies to Gocovri) renal dysfunction
Major Potential Hazard, High plausibility.
Amantadine is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance. Therapy with amantadine should be administered cautiously in patients with renal impairment. Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.
Amantadine (applies to Gocovri) seizure disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Seizures
Amantadine may rarely precipitate or exacerbate seizure activity. Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.
Dopamine agonists (applies to Gocovri) hypotension
Major Potential Hazard, Moderate plausibility.
Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.
Dopaminergic antiparkinson agents (applies to Gocovri) psychosis
Major Potential Hazard, Moderate plausibility.
Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.
Amantadine (applies to Gocovri) CHF/edema
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention
Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure. Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition. Dosage adjustments may be necessary.
Amantadine (applies to Gocovri) hypotension
Moderate Potential Hazard, Moderate plausibility.
Amantadine may occasionally cause orthostatic hypotension. Patients with hypotension should be monitored for exacerbation of their condition during therapy with amantadine. Dosage adjustments may be necessary, and patients should be advised not to rise abruptly from a sitting or recumbent position.
Gocovri drug interactions
There are 128 drug interactions with Gocovri (amantadine).
More about Gocovri (amantadine)
- Gocovri consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.